ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 231.13% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/04/2023 | 32.45% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 198.01% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 297.35% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 231.13% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 297.35% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 231.13% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 231.13% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 231.13% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | -0.66% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 32.45% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 32.45% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 32.45% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 65.56% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 231.13% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 429.8% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 429.8% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 164.9% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1158.28% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1092.05% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1224.5% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1224.5% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 2085.43% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2549.01% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 09/19/2018 | 2217.88% | Evercore ISI Group | → $35 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/07/2023 | 231.13% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 08/04/2023 | 32.45% | 查尔丹资本 | →$2 | 重申 | 中性→中性 |
| 2023年05月17日 | 198.01% | 康托·菲茨杰拉德 | $5→$4.5 | 维护 | 超重 |
| 2023年05月17日 | 297.35% | JMP证券 | →$6 | 重申 | 市场表现优于→市场表现 |
| 2023年05月17日 | 231.13% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 03/30/2023 | 297.35% | JMP证券 | →$6 | 重申 | →市场跑赢大盘 |
| 03/30/2023 | 231.13% | HC Wainwright公司 | $1.5→$5 | 维护 | 买 |
| 2022年12月23日 | 231.13% | 雷蒙德·詹姆斯 | $2→$5 | 维护 | 跑赢大盘 |
| 2022年12月22日 | 231.13% | 康托·菲茨杰拉德 | $0.8→$5 | 升级 | 中性→超重 |
| 2022年08月15日 | -0.66% | HC Wainwright公司 | $2→$1.5 | 维护 | 买 |
| 2022年08月12日 | - | 查尔丹资本 | 评级下调 | 购买→中性 | |
| 2022年08月12日 | 32.45% | 雷蒙德·詹姆斯 | →$2 | 升级 | 市场表现优于→ |
| 05/09/2022 | 32.45% | HC Wainwright公司 | $4→$2 | 维护 | 买 |
| 05/06/2022 | 32.45% | 查尔丹资本 | $2.5→$2 | 维护 | 买 |
| 04/14/2022 | 65.56% | 查尔丹资本 | $8→$2.5 | 维护 | 买 |
| 04/14/2022 | 231.13% | JMP证券 | $8→$5 | 维护 | 市场表现强于大盘 |
| 02/14/2022 | 429.8% | 查尔丹资本 | $18→$8 | 维护 | 买 |
| 02/14/2022 | 429.8% | JMP证券 | $29→$8 | 维护 | 市场表现强于大盘 |
| 02/14/2022 | 164.9% | HC Wainwright公司 | $20→$4 | 维护 | 买 |
| 02/14/2022 | - | 雷蒙德·詹姆斯 | 评级下调 | 强劲的购买→市场表现 | |
| 02/01/2022 | 1158.28% | 雷蒙德·詹姆斯 | →$19 | 开始承保 | →强势购买 |
| 08/09/2021 | 1092.05% | 查尔丹资本 | $20→$18 | 维护 | 买 |
| 05/03/2021 | 1224.5% | Stifel | →$20 | 开始承保 | →购买 |
| 2020年08月11日 | 1224.5% | 查尔丹资本 | $25→$20 | 维护 | 买 |
| 2019年11月19日 | 2085.43% | 花旗集团 | $40→$33 | 维护 | 买 |
| 2018年11月14日 | 2549.01% | 康托·菲茨杰拉德 | →$40 | 开始承保 | →超重 |
| 2018年09月19日 | 2217.88% | Evercore ISI集团 | →$35 | 开始承保 | →跑赢大盘 |
What is the target price for ProQR Therapeutics (PRQR)?
ProQR治疗(PRQR)的目标价格是多少？
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $5.00 expecting PRQR to rise to within 12 months (a possible 231.13% upside). 12 analyst firms have reported ratings in the last year.
2023年8月7日，HC Wainwright&Co.报道了ProQR治疗公司(纳斯达克：PRQR)的最新目标价。这家分析公司将目标价定为5美元，预计第二季度价格将在12个月内上升(可能上涨231.13%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
ProQR治疗公司(PRQR)的最新分析师评级是什么？
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by HC Wainwright & Co., and ProQR Therapeutics reiterated their buy rating.
纳斯达克(代码：PRQR)的最新分析师评级由HC Wainwright&Co.提供，ProQR治疗公司重申其买入评级。
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
ProQR治疗(PRQR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与ProQR治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。ProQR治疗公司的上一次评级是在2023年8月7日提交的，所以你应该预计下一次评级将在2024年8月7日左右提供。
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
分析师对ProQR Treeutics(PRQR)的评级正确吗？
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $0.00 to $5.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.51, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的ProQR治疗(PRQR)评级被重申，目标价在0.00美元至5.00美元之间。ProQR治疗公司(PRQR)目前的交易价格为1.51美元，在分析师的预测范围内。